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Abstract7Adenosine tonically inhibits synaptic transmission through actions at A1 receptors. It also facilitates synaptic
transmission, but it is unclear if this facilitation results from pre- and/or postsynaptic A2A receptor activation or from
indirect control of inhibitory GABAergic transmission. The A2A receptor agonist, CGS 21680 (10 nM), facilitated
synaptic transmission in the CA1 area of rat hippocampal slices (by 14%), independent of whether or not GABAergic
transmission was blocked by the GABAA and GABAB receptor antagonists, picrotoxin (50 WM) and CGP 55845 (1 WM),
respectively. CGS 21680 (10 nM) also inhibited paired-pulse facilitation by 12%, an e¡ect prevented by the A2A receptor
antagonist, ZM 241385 (20 nM). These e¡ects of CGS 21680 (10 nM) were occluded by adenosine deaminase (2 U/ml)
and were made to reappear upon direct activation of A1 receptors with N6-cyclopentyladenosine (CPA, 6 nM). CGS
21680 (10 nM) only facilitated (by 17%) the Kþ-evoked release of glutamate from superfused hippocampal synaptosomes
in the presence of 100 nM CPA. This e¡ect of CGS 21680 (10 nM), in contrast to the isoproterenol (30 WM) facilitation of
glutamate release, was prevented by the protein kinase C inhibitors, chelerythrine (6 WM) and bisindolylmaleimide (1 WM),
but not by the protein kinase A inhibitor, H-89 (1 WM). Isoproterenol (30 WM), but not CGS 21680 (10^300 nM),
enhanced synaptosomal cAMP levels, indicating that the CGS 21680-induced facilitation of glutamate release involves a
cAMP-independent protein kinase C activation. To discard any direct e¡ect of CGS 21680 on adenosine A1 receptor, we
also show that in autoradiography experiments CGS 21680 only displaced the adenosine A1 receptor antagonist, 1,3-
dipropyl-8-cyclopentyladenosine ([3H]DPCPX, 0.5 nM) with an EC50 of 1 WM in all brain areas studied and CGS 21680
(30 nM) failed to change the ability of CPA to displace DPCPX (1 nM) binding to CHO cells stably transfected with A1
receptors.
Our results suggest that A2A receptor agonists facilitate hippocampal synaptic transmission by attenuating the tonic
e¡ect of inhibitory presynaptic A1 receptors located in glutamatergic nerve terminals. This might be a ¢ne-tuning role for
adenosine A2A receptors to allow frequency-dependent plasticity phenomena without compromising the A1 receptor-
mediated neuroprotective role of adenosine. H 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.
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In several areas of the CNS, adenosine plays an impor-
tant role as a neuromodulator. Particularly in the hippo-
campus, the most highly expressed A1 receptors are
responsible for the inhibitory e¡ects mediated by adeno-
sine in synaptic transmission and neuronal excitability
(Dunwiddie and Masino, 2001). In recent years, how-
ever, it has been demonstrated that low concentrations
of the adenosine A2A receptor agonist, CGS 21680, trig-
ger facilitatory responses, suggesting the existence of
facilitatory adenosine A2A receptors (for a review see
Sebastia‹o and Ribeiro, 1996). In the hippocampus,
adenosine may therefore exert a dual regulation of syn-
aptic transmission via these two subtypes of receptors
(Cunha, 2001).
The mechanism by which activation of adenosine A1
receptors leads to inhibition of transmitter release is rea-
sonably well understood (Thompson et al., 1992;
Ambro¤sio et al., 1997). By contrast, the way in which
A2A receptors a¡ect neurotransmission is less clear. It
has been proposed that A2A receptors could presynapti-
cally facilitate glutamate release (Cunha et al., 1997; Li
and Henry, 1998), but some electrophysiologically
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Abbreviations: ADA, adenosine deaminase; CGP 55845, 3-N-[1-(S)-
(3,4-dichlorophenyl)ethyl]amino-2-(S)-hydroxypropyl-P-benzyl-
phosphinic acid; CGS 21680, 2-[4-(2-p-carboxyethyl)phenyl-
amino]-5P-N-ethylcarboxamidoadenosine; CHO, Chinese hamster
ovary; CPA, N6-cyclopentyladenosine; DMSO, dimethylsulfox-
ide; DPCPX, 1,3-dipropyl-8-cyclopentylxanthine; EDTA, ethyl-
enediaminetetra-acetate ; fEPSP, ¢eld excitatory postsynaptic
potential ; H-89, N-[2-((p-bromocinnamyl)amino)ethyl]5-isoqui-
nolinesulfonamide; HEPES, N-(2-hydroxyethyl)piperazine-NP-(2-
ethanesulfonic acid) ; HPLC, high-performance liquid chromatog-
raphy; LTP, long-term potentiation; PKA, protein kinase A;
PKC, protein kinase C; PPF, paired-pulse facilitation; Rolipram,
[4-(3P-cyclopentyloxy-4P-methoxyphenyl)-2-pyrrolidone] ; R-PIA,
N6-R-phenylisopropyladenosine; ZM 241385, 4-(2-{7-amino-2(2-
furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol.
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recorded A2A receptor-mediated e¡ects in hippocampal
slices may be attributed to a postsynaptic site of action
(Li and Henry, 1998; O’Kane and Stone, 1998). Also,
since there is a tight A1/A2A receptor interaction (Dixon
et al., 1997; Lopes et al., 1999a), it is unclear whether the
function of A2A receptors is to directly control neuro-
transmitter release (Sebastia‹o and Ribeiro, 1996) or,
alternatively, to attenuate the tonic inhibitory action of
A1 receptors (Lopes et al., 1999a). Finally, since excita-
tory synaptic transmission in the hippocampus is under
GABAergic control (Buckmaster and Soltesz, 1996), it is
possible that A2A receptor-mediated facilitation results
from interference with the GABAergic system (Cunha
and Ribeiro, 2000a), as proposed in other brain areas
(Phillis, 1998; Edwards and Robertson, 1999).
We therefore investigated if the action of adenosine
A2A receptors in the rat hippocampus depends on
GABAergic function or if it is a direct e¡ect on gluta-
matergic nerve terminals controlling the release of neuro-
transmitter. We also tested if the facilitatory e¡ects
observed when A2A receptors are activated mainly result
from an attenuation of tonic A1 receptor responses.
EXPERIMENTAL PROCEDURES
Drugs
N6-Cyclopentyladenosine (CPA), 1,3-dipropyl-8-cyclopentyla-
denosine (DPCPX) and CGS 21680 were from RBI (Natick,
MA, USA), chelerythrine, bisindolylmaleimide and H-89 were
from Calbiochem (Darmstadt, Germany), isoproterenol, propa-
nol, picrotoxin and N6-R-phenylisopropyladenosine (R-PIA)
were from Sigma (St. Louis, MO, USA), ZM 241385 was
from Tocris Cookson (Bristol, UK), [3H]DPCPX (speci¢c activ-
ity 110.6 Ci/mmol) was from DuPont NEN (Stevenage,
Hertfordshire, UK) and [3H]glutamate (speci¢c activity 45 Ci/
mmol) was from Amersham (Buckinghamshire, UK). Rolipram
was provided by Schering and CGP 55845 was supplied by Ciba
Geigy. All cell culture solutions were from Gibco.
CPA, CGS 21680, chelerythrine, bisindolylmaleimide, H-89
and ZM 241385 were made up to a 5 mM stock solution in
dimethylsulfoxide (DMSO) and rolipram was made up in a
50 mM stock solution in DMSO. DPCPX and CGP 55485
were made up into 5 mM stocks in 99% DMSO and 1%
NaOH 1 M and picrotoxin was made up to a 50 mM stock
solution in ethanol. Aqueous dilution of these stock solutions
was made daily.
Electrophysiological recordings of hippocampal synaptic
transmission
Field excitatory postsynaptic potentials (fEPSPs) were
recorded in the CA1 area of hippocampal slices obtained from
male Wistar rats (5^6 weeks old; Harlan Iberica, Barcelona,
Spain), handled according to the European guidelines (86/609/
EEC), as previously described (e.g. Cunha et al., 1994). A cut
was made to separate the CA1 from the CA3 region to prevent
propagation of epileptiform activity. The intensity of the stim-
ulus was adjusted to evoke a fEPSP with an amplitude of 0.7^1
mV without appreciable population spike contamination and
responses were quanti¢ed as the initial slope of the averaged
fEPSPs (Anderson and Collingridge, 1997). In all of the experi-
ments, the data were analyzed as mean percentage change in
response slope when compared with responses obtained during
the control period.
To elicit paired-pulse facilitation, the Scha¡er pathway was
stimulated twice with 50-ms inter-pulse interval and the synaptic
facilitation was quanti¢ed as the ratio (P2/P1) between the slopes
of the fEPSP elicited by the second (P2) and the ¢rst (P1) stim-
uli.
[3H]Glutamate release from hippocampal nerve terminals
The evoked release of [3H]glutamate was adapted from
Lonart et al. (1998), following a methodology similar to that
used to study the release of GABA and acetylcholine from rat
hippocampal nerve terminals (Cunha et al., 1997; Cunha and
Ribeiro, 2000a). Basically, the synaptosomes were labelled with
[3H]glutamate (0.2 WM) during 5 min at 37‡C, layered over
Whatman GF/C ¢lters and superfused (£ow rate: 0.8 ml/min)
with Krebs solution of the following composition (in mM): 124
NaCl, 3 KCl, 26 NaHCO3, 1.25 NaH2PO4, 1 MgSO4, 2 CaCl2
and 10 glucose, gassed with a 95% O2^5% CO2 mixture. The
synaptosomes were stimulated with 28 mM Kþ (isomolar sub-
stitution of Naþ by Kþ in the Krebs superfusion solution) at
3 and 9 min after starting sample collection (S1 and S2) and test
drugs were added 2 min before S2 onwards. The amount of
radioactivity recovered in the e¥uent of the evoked release
peak was mostly glutamate, since high-performance liquid chro-
matography (HPLC) separation of the e¥uent samples (see
Cunha and Ribeiro, 2000a) showed that 65X 6% (n=4) of
total radioactivity in samples of the synaptosomal superfusate
collected in basal conditions and 89X 4% (n=4) of total radio-
activity in samples collected upon Kþ stimulation was recovered
in the glutamate peak. The evoked release of [3H]glutamate was
essentially Ca2þ-dependent since omission of Ca2þ in the Krebs
solution from 2 min before S2 onwards essentially abolished the
Kþ-evoked tritium release (n=4). Thus, we considered that the
evoked release of tritium in the present experimental conditions
corresponds to a Ca2þ-dependent release of [3H]glutamate.
When we evaluated the changes of the e¡ect of a drug by a
modi¢er, this modi¢er was applied 15 min before the beginning
of sample collection period and was present during S1 and S2.
When present during S1 and S2, CPA (100 nM), chelerythrine
(6 WM), H-89 (1 WM) or propanol (30 WM) did not signi¢cantly
(Ps 0.05) alter the S2/S1 ratio as compared with the S2/S1 ratio
obtained in control conditions (no added drug), and bisindolyl-
maleimide (1 WM) also failed to appreciably modify the S2/S1
ratio.
Autoradiography in brain slices
In order to examine interactions of CGS 21680 with A1 recep-
tors we ¢rst used quantitative autoradiography essentially as
described (Parkinson and Fredholm, 1992). In brief, coronal
sections of rat brain were preincubated with adenosine deami-
nase (ADA), washed, and incubated for 2 h at room temper-
ature with 0.5 nM [3H]DPCPX and increasing (5^5000 nM)
concentrations of CGS 21680 and 1 or 10 mM MgCl2. After
washing, sections were dried and apposed, together with micro-
scales, to Hyper¢lm (Amersham) for 3 weeks. Quantitation was
performed using a MCID M4 system and data analyzed using
GraphPad Prism.
Radioligand binding in transfected CHO cells
Chinese hamster ovary (CHO) cells (CHO-K1 cells; CCL61,
American Type Culture Collection, Rockville, MD, USA) stably
transfected with human adenosine A1 or human A2A receptors
were grown adherent and maintained as described by Klotz et
al. (1998). The whole cell binding assays were performed as
previously described (Gerwins et al., 1990). For saturation
curves, [3H]DPCPX (0^10 nM) was incubated with 150 000^
250 000 cells (counted by the Trypan Blue exclusion method)
in a ¢nal volume of 300 Wl in an incubation solution containing
Dulbecco’s modi¢ed Eagle’s medium (DMEM) bu¡ered with
20 mM HEPES, pH 7.4 (Gerwins et al., 1990). All samples
were assayed in duplicate. The incubation was for 2 h at
room temperature (20^25‡C). Competition curves of the A1
receptor antagonist, [3H]DPCPX, by the A1 receptor agonist,
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CPA, were performed in the absence and in the presence of the
A2A receptor agonist, CGS 21680. The whole cell suspension
(150 000^250 000 cells/well) was incubated with [3H]DPCPX
(1 nM) and 10 di¡erent concentrations of the displacer, CPA
(ranging from 0.1 nM to 1 WM), in DMEM/HEPES, pH 7.4
solution in a ¢nal volume of 300 Wl. The remaining conditions
were the same as described above. The speci¢c binding was
obtained by subtracting the total binding from non-speci¢c
binding, which was measured in the presence of R-PIA
(20 WM) and represented only 10% of total binding. The IC50
values were converted into Ki values by non-linear ¢tting of the
semi-logarithmic curves derived from the competition curves.
An F-test (P6 0.05) was used to determine whether the curves
were best ¢tted by a one or two independent binding site equa-
tion. Protein determination was by Bradford method using Bio-
Rad reagent.
cAMP assays in hippocampal nerve terminals
Hippocampal synaptosomes were prepared as described above
and resuspended in 1 ml gassed Krebs solution also containing
2 U/ml ADA and 50 WM rolipram. A 90-Wl synaptosomal ali-
quot was warmed at 37‡C for 15 min and then incubated at
37‡C for 4 min with gassed Krebs containing ADA and roli-
pram (control) or with this modi¢ed Krebs containing various
concentrations of isoproterenol (30 WM) or CGS 21680 (30^300
nM) without or with CPA (100 nM) in the absence or in the
presence of chelerythrine (6 WM) or H-89 (1 WM). The treated
synaptosomes were then inactivated by boiling for 10 min in 1 ml
of 50 mM Tris/4 mM EDTA, pH 7.6. The levels of cAMP in the
supernatants obtained after sonication and centrifugation
(14 000Ug, 10 min, 4‡C) were quanti¢ed with a radioimmuno-
assay kit (Amersham), as previously described (Lopes et al.,
1999b), and protein measured according to Peterson (1977).
Statistics
The values presented are meanXS.E.M. of n experiments. To
test the signi¢cance of the e¡ect of a drug versus control, a
paired Student’s t-test was used. When making comparisons
from di¡erent sets of experiments with control, a one-way anal-
ysis of variance (ANOVA) was used, followed by a Dunnett’s
test. P9 0.05 was considered to represent a signi¢cant di¡erence.
RESULTS
E¡ect of A2A receptor activation upon blockade of
GABAergic transmission
The release of several neurotransmitters (excitatory
and inhibitory) contributes to the overall response that
is analyzed in a fEPSP (Thompson et al., 1992). We ¢rst
investigated if the result of activation of A2A receptors
on extracellular electrophysiological recordings was de-
pendent on inhibitory GABAergic transmission. In this
set of experiments, the superfusion of hippocampal slices
with the A2A receptor agonist, CGS 21680 (10 nM),
caused a 14.4 X 1.9% (n=4, P6 0.05) facilitation, revers-
ible upon washout, of synaptic transmission in Scha¡er
¢ber/CA1 pyramid synapses (Fig. 1A), a response previ-
ously shown to be mediated by adenosine A2A receptors
since it was prevented by the A2A receptor antagonist,
ZM 241385 (Cunha et al., 1997; Cunha and Ribeiro,
2000b). The addition of the GABAA receptor antagonist,
picrotoxin (50 WM), plus the GABAB receptor antago-
nist, CGP 55845 (1 WM), caused a 26.3X 2.4% (n=3)
facilitation of fEPSP slope, as a consequence of remov-
ing the GABAergic inhibitory action. However, the facil-
itatory e¡ect of CGS 21680 (10 nM) on synaptic
transmission remained intact after this GABAergic
blockade (Fig. 1). Facilitation of fEPSP slope caused
by CGS 21680 (10 nM) was 16.3 X 2.7% (n=3,
P6 0.05) in the absence and 17.9X 3.8% (n=3,
P6 0.05) in the presence of picrotoxin (50 WM) plus
CGP 55845 (1 WM). This indicates that the de¢ned A2A
receptor-mediated facilitation of synaptic transmission is
independent of GABAergic transmission and that led us
to investigate the e¡ect of CGS 21680 on the glutama-
tergic transmission.
E¡ect of A2A receptor activation on paired-pulse
facilitation
When two consecutive pulses are applied to the a¡er-
ent Scha¡er ¢bers with an interval of 50 ms, the fEPSP
response to the second pulse is increased as a result of
presynaptic calcium accumulation. Modi¢cation of this
phenomenon, called paired-pulse facilitation (PPF), is an
indication of a presynaptic action in the control of glu-
tamatergic nerve terminals (Wu and Saggau, 1994).
When PPF is increased by a drug it suggests an inhibi-
tion of glutamate release and when PPF is decreased it
suggests a facilitation of glutamate release (Thompson et
al., 1992). As shown in Fig. 2, CGS 21680 (10 nM)
inhibited by 12.3 X 1.4% (P6 0.05, n=5) PPF while si-
multaneously facilitating the fEPSP slope. In three of
these experiments, we found that ZM 241385 (20 nM)
blocked the ability of CGS 21680 to inhibit PPF. By
itself, ZM 241385 (20 nM) was devoid of measurable
e¡ects on PPF. This is a strong suggestion that the
studied A2A receptor agonist acts presynaptically, facili-
tating glutamate release and therefore facilitating the
fEPSP response.
E¡ect of A2A receptor activation on glutamate release
To directly demonstrate that the action of the A2A
receptor agonist occurs at the presynaptic level, we
studied its e¡ect on glutamate release from nerve termi-
nals. When hippocampal synaptosomes, previously
loaded with [3H]glutamate, were stimulated for 30 s
with 28 mM Kþ, they released tritium in a Ca2þ-depen-
dent manner that is mostly [3H]glutamate, as assessed by
HPLC (see Experimental procedures). Two periods of
chemical stimulation (S1 and S2), separated by a 6-min
interval, produced a similar evoked tritium release
(Fig. 3A, B), with an S2/S1 ratio of 0.89X 0.02 (n=15).
As illustrated in Fig. 3A, application of CGS 21680
(10 nM) 2 min before the second stimulation period
(S2) failed to modify the Kþ-evoked release of tritium.
The S2/S1 ratio was of 0.75X 0.07 in control conditions
and of 0.71X 0.13 when CGS 21680 was present (n=4).
This lack of e¡ect of CGS 21680 (10 nM) is not due to a
general inability to facilitate the evoked release of gluta-
mate from hippocampal nerve terminals, since the L-ad-
renergic receptor agonist, isoproterenol (30 WM),
facilitated the evoked release of glutamate (Fig. 3C, D).
This e¡ect of isoproterenol was antagonized by the L-ad-
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renergic receptor antagonist propanol (30 WM, n=4). To
exclude that the lack of e¡ect of CGS 21680 on the
evoked release of glutamate might result from an insu⁄-
cient period of equilibration of CGS 21680, we tested the
e¡ect of CGS 21680 (10 nM) applied 6 min before S2.
Under these conditions, which were used to show the
facilitatory e¡ect of CGS 21680 (10 nM) on the evoked
release of acetylcholine and of GABA from the same
Fig. 1. Comparison of the e¡ects of the adenosine A2A receptor agonist, CGS 21680 (10 nM), on synaptic transmission in rat
hippocampal slices in the absence and in the presence of the GABAA receptor antagonist, picrotoxin (50 WM), and of the
GABAB receptor antagonist, CGP 55845 (1 WM). (A) Averages of the slopes of eight consecutive fEPSPs recorded from the
CA1 area of a hippocampal slice, which was ¢rst superfused with CGS 21680 (10 nM), then washed out, then with picrotoxin
(50 WM) and CGP 55845 (1 WM), then with CGS 21680 (10 nM) in the presence of picrotoxin (50 WM) and CGP 55845
(1 WM), as indicated by the upper horizontal bars. The superimposed fEPSPs presented in B were obtained in (a) before
adding any drug to the superfusion solution and 20^24 min after application of CGS 21680 (10 nM), and in (b) 20^24 min
after adding picrotoxin (50 WM) and CGP 55845 (1 WM) and 20^24 min after application of CGS 21680 (10 nM) in the
presence of picrotoxin (50 WM) and CGP 55845 (1 WM). Scale bars = 500 WV, 5 ms. (C) The ordinates represent the average
percentage increase of fEPSP slope caused by CGS 21680 (10 nM) in the absence (n=3, control fEPSP slope of 0.42X 0.03
WV/ms) and in the presence of picrotoxin (50 WM) and CGP 55845 (1 WM) (n=3, control fEPSP slope of 0.43 X 0.03 WV/ms).
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preparation (Cunha et al., 1997; Cunha and Ribeiro,
2000a), CGS 21680 (10 nM) was still devoid of e¡ects on
the evoked release of glutamate (n=2, data not shown).
Finally, we tested the e¡ect of a higher concentration of
CGS 21680. At a concentration of 30 nM, CGS 21680
was still devoid of e¡ects on the evoked release of
glutamate (S2/S1 ratio: control = 0.82X 0.14; test =
0.85X 0.13, n=5) and higher concentrations of CGS
21680 were not tested since they were previously shown
to produce a lower or no e¡ect, possibly due to desensi-
tization of A2A receptors (e.g. Cunha et al., 1997; Cunha
and Ribeiro, 2000a).
Role of tonic A1 receptor-mediated inhibition for
A2A receptor facilitation
The lack of e¡ect of the tested A2A receptor agonist
alone on the evoked release of glutamate from super-
fused hippocampal synaptosomes was in marked con-
trast to its e¡ect on PPF in hippocampal slices. One
hypothesis to be tested was that the facilitation of syn-
aptic transmission mediated by CGS 21680 depends on
attenuation of a tonic A1 receptor-mediated inhibition,
since we reported earlier that A2A receptor activation
reduces A1 receptor responses (Lopes et al., 1999a). In
hippocampal slices, the selective A1 receptor antagonist,
DPCPX (20 nM), facilitated by 21X 3% (n=3, P6 0.05)
fEPSP slope, indicating that endogenous adenosine is
tonically activating inhibitory A1 receptors to depress
synaptic transmission (e.g. Dunwiddie and Diao, 1994).
In contrast, DPCPX (20 nM, applied 2 or 6 min before
S2) was devoid of e¡ects on the evoked release of gluta-
mate from hippocampal synaptosomes (S2/S1 ratio of
0.92X 0.08 in the absence and 0.91X 0.09 in the presence
of 20 nM DPCPX, n=4). This indicates the absence of a
tonic A1 receptor-mediated control of the evoked release
of glutamate, possibly due to the fast washout of extra-
cellular adenosine upon superfusion of the diluted syn-
aptosomes. Indeed, such dilution of agonist explains the
lack of e¡ect of many di¡erent antagonists of presynap-
tic neuromodulatory systems when tested in superfused
nerve terminals (see Nicholls, 1989).
To investigate if the lack of e¡ect of CGS 21680 on the
evoked release of glutamate might be due to this absence
of tonic A1 receptor-mediated inhibition, we tested the
e¡ect of CGS 21680 (10 nM) in the presence of an A1
receptor agonist, CPA (100 nM), that has previously
been shown to inhibit the evoked release of glutamate
from rat hippocampal synaptosomes (Ambro¤sio et al.,
1997). In the presence of CPA (100 nM), present during
S1 and S2, addition of CGS 21680 (10 nM) 2 min before
S2 now facilitated the evoked release of glutamate
(Fig. 4A), an e¡ect prevented by the A2A receptor antag-
onist, ZM 241385 (20 nM) (n=4) (Fig. 4A).
To further demonstrate that the tested A2A receptor
agonist only facilitates glutamatergic transmission if a
tonic A1 receptor inhibition is present, we compared
the e¡ect of CGS 21680 (10 nM) both on synaptic trans-
mission and on PPF upon removing endogenous adeno-
sine with the use of ADA (which converts adenosine into
its inactive metabolite inosine) and then re-admitting A1
receptor activation with the use of the non-metabolizable
and selective A1 receptor agonist, CPA, still in the pres-
ence of ADA. The concentration of ADA tested (2 U/ml)
has been shown earlier to be e¡ective in removing endog-
enous adenosine (Sebastia‹o et al., 2000). As illustrated in
Fig. 4B, ADA (2 U/ml) caused a 18.5X 1.5% (n=3,
P6 0.05) facilitation of fEPSP slope, consistent with its
ability to remove a tonic inhibition of synaptic transmis-
sion by endogenous adenosine. In the presence of ADA
(2 U/ml), CGS 21680 (10 nM) failed to modify synaptic
transmission (Fig. 4B). Still in the presence of ADA (2 U/
Fig. 2. Representative experiment illustrating the e¡ects of the adenosine A2A receptor agonist, CGS 21680 (10 nM), on
synaptic transmission and on PPF recorded in the same experiment in rat hippocampal slices. The open symbols are the
averages of the slopes of eight consecutive fEPSPs recorded from the CA1 area of a hippocampal slice that was superfused
with CGS 21680 (10 nM) as indicated in the upper bar. The ¢lled symbols represent the average of eight PPF (50-ms inter-
val) of fEPSPs, quanti¢ed as the ratio (P2/P1) between the slope of the response to the second stimulus (P2) and the slope of
the response to the ¢rst stimulus (P1).
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ml), CPA (6 nM) caused a 44.3 X 2.3% (n=3, P6 0.05)
inhibition of fEPSP slope, an e¡ect previously shown to
be mediated by A1 receptors (Alzheimer et al., 1991;
Sebastia‹o et al., 2000). Finally, upon direct activation
of A1 receptors with CPA still in the presence of ADA,
we now observed that CGS 21680 (10 nM) facilitated the
fEPSP slope by 17.1X 1.0% (n=3, P6 0.05). This ability
of CGS 21680 to facilitate synaptic transmission likely
results from a presynaptic site of action, since the e¡ects
of CGS 21680 (10 nM) on PPF were a mirror image of
the e¡ects of CGS 21680 on fEPSP slope. In fact, as
illustrated in Fig. 4B, CGS 21680 (10 nM) was devoid
of e¡ects on PPF in the presence of ADA (2 U/ml, which
by itself decreased PPF by 13.7X 1.0%, n=3, P6 0.05)
but caused a 13.1X 1.7% (n=3, P6 0.05) inhibition of
PPF in the simultaneous presence of ADA (2 U/ml) and
CPA (6 nM, which by itself caused a 29.1X 0.4% facili-
tation of PPF, n=3, P6 0.05).
E¡ect of CGS 21680 on adenosine A1 receptor binding
The above results would be compatible with a direct
interaction of CGS 21680 with A1 receptors. However, in
most binding studies CGS 21680 has been shown to have
a very weak e¡ect on binding of either agonists or antag-
onists at A1 receptors. Previous results had shown that
binding of [3H]CGS 21680 to rat brain is strongly mag-
nesium-dependent (Johansson et al., 1992), but most pre-
vious studies on A1 binding of CGS 21680 had used only
low concentrations of this cation. We therefore per-
formed studies of CGS 21680 displacement of the A1
receptor antagonist radioligand [3H]DPCPX at 1 and
10 mM Mg concentration. As seen from the results in
Table 1, CGS 21680 was a weak displacing agent in all
brain regions using the lower magnesium concentration,
in con¢rmation of previous results. IC50 values were
close to 1 WM in all brain regions studied. The same
was true in cortex, caudate^putamen and the CA3 region
of hippocampus at 10 mM magnesium. However, in the
CA1 region, 30% (95% con¢dence interval: 9^46%, n=3)
of the [3H]DPCPX binding was displaced by CGS 21680
with an IC50 value of 44 nM.
To further explore if low nanomolar concentrations of
CGS 21680 could directly interfere with A1 receptors, we
tested the e¡ects of CGS 21680 in heterologously
expressed A1 receptors. We have carried out these experi-
Fig. 3. Lack of e¡ect of the adenosine A2A receptor agonist, CGS 21680 (10 nM), and facilitation by the L-receptor agonist,
isoproterenol (30 WM), of glutamate release from rat hippocampal synaptosomes. (A, C) Time course of tritium release that
was con¢rmed to be essentially [3H]glutamate release. The preparation was challenged with two periods of stimulation with
20 mM Kþ (S1 and S2), as indicated by the bars above the abscissa. The open symbols represent tritium release from a
control chamber, to which no drug was added, and the ¢lled symbols represent the tritium release of the test chamber, to
which either CGS 21680 (10 nM; in A) or isoproterenol (30 WM; in C) was added through the superfusate, as indicated by
the upper bar. (B, D) Average e¡ect of CGS 21680 (10 nM; in B) or isoproterenol (30 WM; in D). The results are meanX
S.E.M. of four experiments. *P6 0.05.
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ments using human A1 and A2A receptors, since no
major di¡erences were previously found in terms of the
binding characteristics of the tools used (DPCPX, CPA
and CGS 21680) to rat and human A1 and A2A receptors
(see Klotz et al., 1998). CGS 21680 (30 nM) failed to
modify the ability of CPA (0.1 nM^1 WM) to displace
[3H]DPCPX (1 nM) binding to CHO cells stably trans-
fected with human A1 receptors [in control condition,
Ki = 122.0 nM (95% con¢dence interval : 52.0^288.0
nM, n=2) and in the presence of 30 nM CGS 21680,
Ki = 61.0 nM (95% con¢dence interval: 24.0^153.0 nM,
n=2)]. Both curves were best ¢tted by a one independent
binding site equation. As a control for the selectivity of
[3H]DPCPX (1 nM) labelling of A1 receptors, we con-
¢rmed that [3H]DPCPX (0^10 nM) failed to bind to
CHO cells stably transfected with A2A receptors (maxi-
mal speci¢c binding of 1.42 X 0.26 fmol/106 cells, n=2).
Transducing system operated by A2A receptors to
attenuate A1 receptor-mediated inhibition
Although A2A receptors are classically classi¢ed as
being coupled to the GS/adenylate cyclase/cAMP path-
way (Fredholm et al., 1994), we have previous reports of
the involvement of protein kinase C (PKC) in response
to A2A receptor agonists (Lopes et al., 1999a; Cunha and
Ribeiro, 2000b). However, it is unclear if PKC activity is
directly controlled by A2A receptors or if it is a conse-
quence of an increase of cAMP levels within nerve ter-
minals once A2A receptors are activated (Gubitz et al.,
1996). We directly quanti¢ed the cAMP levels in hippo-
campal nerve terminals and compared the e¡ects of CGS
21680 and of isoproterenol thereupon. As illustrated in
Fig. 5A, isoproterenol enhanced cAMP levels in hippo-
campal nerve terminals, as previously shown to occur in
rat cortical nerve terminals (Herrero and Sa¤nchez-Prieto,
1996). In contrast to the e¡ect of isoproterenol, CGS
21680 (10 nM), either in the absence or in the presence
of CPA (100 nM), failed to modify cAMP levels
(Fig. 5A). Since we had previously observed that the
concentration range required to detect CGS 21680-
induced cAMP increases is nearly 10-fold greater than
that required to facilitate neurotransmitter release in
other CNS preparations (Lopes et al., 1999b), we tested
the e¡ect of higher concentrations of CGS 21680 on
cAMP levels. But, again, either with or without CPA
(100 nM), CGS 21680 in concentrations of 100 nM or
300 nM failed to modify cAMP levels (n=2 for each
condition, data not shown). Note that activation of A1
receptors failed to cause measurable changes in cAMP
levels (Fig. 5A), although CPA (100 nM) decreased
cAMP levels upon stimulation with 30 WM isoproterenol
(n=2, data not shown) in accordance with the known
ability of A1 receptors to decrease the evoked accumu-
lation of cAMP (e.g. Dunwiddie and Fredholm, 1989).
Finally, we compared the e¡ect of inhibitors of protein
kinase A (PKA) or of PKC on the facilitatory e¡ects of
CGS 21680 (in the presence of 100 nM CPA) and of
isoproterenol on the evoked release of glutamate. As
illustrated in Fig. 5B, the facilitatory e¡ect of CGS
Table 1. Potency of CGS 21680 to displace [3H]DPCPX (0.5 nM)
binding to coronal sections of rat brain in media containing
di¡erent magnesium concentrations
Region 1 mM Mg2þ 10 mM Mg2þ
Cortex 1420 (844^2389) 1005 (614^1645)
Caudate^putamen 998 (562^1769) 531 (283^995)
Hippocampus CA3 988 (591^1650) 1321 (666^2653)
Hippocampus CA1 1125 (991^1277) 44 (8^240)
(30% displacement)
1950 (1052^3616)
The IC50 values are presented in nM as mean (95% con¢dence
interval) from three experiments.
Fig. 4. Facilitatory e¡ect of the A2A receptor agonist, CGS 21680
(10 nM), on the evoked release of glutamate from hippocampal
nerve terminals in the presence of the A1 receptor agonist, CPA
(100 nM) (A), and comparison of the e¡ect of CGS 21680 (10 nM)
on synaptic transmission and PPF in rat hippocampal slices in the
absence and presence of A1 receptor activation (B). (A) The ordi-
nates represent tritium release, which is a good measure of
[3H]glutamate release, from rat hippocampal synaptosomes, mea-
sured as the ratio between two pulses of stimulation with 20 mM
Kþ (S1 and S2). CGS 21680 (10 nM), added 2 min before S2,
facilitated the evoked tritium out£ow when CPA (100 nM) was
present during S1 and S2, and this e¡ect was prevented by the
A2A receptor antagonist, ZM 241385 (20 nM). Thus, application
of CGS 21680 in the presence of ZM 241385 and CPA did not
produce a statistically signi¢cant increase in glutamate release
compared to CPA alone. The results are meanXS.E.M. of four to
six experiments. *P6 0.05. (B) An experiment where fEPSPs (open
symbols) and PPF (50-ms interval ; ¢lled symbols) were recorded
in the same experiment in the CA1 area of a rat hippocampal
slice which was ¢rst superfused with ADA (2 U/ml), then with
CGS 21680 (10 nM) in the presence of ADA (2 U/ml). Then CGS
21680 was washed out and CPA (6 nM) was added, still in the
presence of ADA (2 U/ml), and ¢nally ¢rst CGS 21680 and then
CPA were washed out, as shown in the horizontal bars.
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21680 (10 nM), in the presence of 100 nM CPA, on the
evoked release of glutamate was prevented by the PKC
inhibitor, chelerythrine (6 WM), but not by the PKA
inhibitor, H-89 (1 WM). This is in close agreement with
the ability of di¡erent PKC inhibitors, but not of drugs
a¡ecting cAMP/PKA, to prevent CGS 21680-induced
facilitation of hippocampal synaptic transmission. In
two experiments we con¢rmed that another PKC inhib-
itor, bisindolylmaleimide (1 WM), also attenuated (68^
92%) the facilitatory e¡ect of CGS 21680 (10 nM), in
the presence of 100 nM CPA, on the evoked release of
glutamate. In contrast, the facilitatory e¡ect of isoproter-
enol (30 WM) on the evoked release of glutamate was
prevented by the PKA inhibitor, H-89 (1 WM), but not
by the PKC inhibitor, chelerythrine (6 WM). These obser-
vations, together with the previous observation of the
di¡erential e¡ects of CGS 21680 and of isoproterenol
on cAMP levels, exclude the possibility that PKC acti-
vation might result from a rise in cAMP levels, since
isoproterenol increased cAMP levels but increased gluta-
mate release through a PKC-independent mechanism.
DISCUSSION
The present results show that the facilitation of hippo-
campal synaptic transmission mediated by a selective
adenosine A2A receptor agonist is not a direct e¡ect,
but instead results from a presynaptic attenuation of
A1 receptor response. This conclusion derives from the
observed ability of the prototypical A2A receptor agonist
CGS 21680 to facilitate glutamate release and synaptic
transmission as well as to inhibit PPF but only when a
tonic A1 receptor-mediated inhibition is present. In fact,
these e¡ects were abolished upon removal of endogenous
extracellular adenosine.
For several reasons it is unlikely that the observed
e¡ects of CGS 21680 are due to a direct antagonism
by CGS 21680 of the e¡ects of adenosine at A1 recep-
tors. (1) Numerous studies have shown that CGS 21680
binds poorly to A1 receptors with a Ki close to 1 WM.
These ¢ndings, which were again replicated here, indicate
that at the concentration used in the present experiments
(10 nM) very few A1 receptors would be occupied by
CGS 21680. (2) There is no evidence that CGS 21680
could act as an A1 receptor antagonist. In CHO cells
heterologously expressing A1 receptors, CGS 21680
failed to a¡ect the displacement by an A1 receptor ago-
nist of the binding of the A1 receptor antagonist,
DPCPX. Also, DPCPX did not bind to heterologously
expressed A2A receptors. (3) The attenuation by CGS
21680 of tonic A1 receptor inhibition observed in hippo-
campal slices and synaptosomes was prevented by low
nanomolar concentrations of the selective A2A receptor
antagonist, ZM 241385, which only binds A1 receptors at
micromolar concentrations (Poucher et al., 1995).
Even though these and earlier observations strongly
indicate that the e¡ects of CGS 21680 are due to activa-
tion of A2A receptors, alternative explanations cannot be
excluded. It has been shown that most of the binding of
CGS 21680 in hippocampus is to a site di¡erent from
classical A2A receptors (Johansson et al., 1993; Cunha et
al., 1996, 1999; Lindstro«m et al., 1996). These binding
sites are characterized among others by being sensitive to
DPCPX. In the present study we found that a small, but
signi¢cant, proportion of the DPCPX binding sites only
in the CA1 area of the hippocampus could be displaced
by CGS 21680 in nanomolar concentrations. Thus, it
may be that adenosine A1 receptors, adenosine A2A
receptors or some other entity might display binding
sites with a pharmacology that shows hybrid A1/A2A
characteristics. It cannot be completely excluded that
such an entity is partially responsible for the interactions
observed here. Nevertheless, the most parsimonious
interpretation is that the CGS 21680 facilitatory e¡ects
are dependent on A1/A2A receptor interaction. In situ
Fig. 5. L-Adrenergic receptor activation but not A2A receptor acti-
vation enhanced the levels of cAMP in hippocampal nerve termi-
nals and the A2A receptor-induced facilitation, in contrast to the
L-receptor-induced facilitation, of the evoked release of glutamate
is dependent on PKC activation but not PKA activation. (A) The
ability of isoproterenol (30 WM) to enhance the levels of cAMP in
hippocampal nerve terminals, whereas CGS 21680 (30 nM), CPA
(100 nM) or the simultaneous presence of CGS 21680 (30 nM)
and CPA (100 nM) was devoid of e¡ects. (B) The enhancement of
the Kþ-evoked release of [3H]glutamate from hippocampal nerve
terminals (subjected to two periods of stimulation with 20 mM
Kþ, S1 and S2) by CGS 21680 (30 nM, added 2 min before S2
with 100 nM CPA present during S1 and S2) and by isoproterenol
(30 WM, added 2 min before S2). The PKC inhibitor, chelerythrine
(6 WM, present during S1 and S2), but not the PKA inhibitor,
H-89 (1 WM, present during S1 and S2), prevented the facilitation
of the evoked release of glutamate by CGS 21680 (30 nM, in the
presence of 100 nM CPA), whereas the facilitatory e¡ect of iso-
proterenol (30 WM) was prevented by H-89 (1 WM), but not by
chelerythrine (6 WM). The results are meanXS.E.M. of four
experiments. *P6 0.05.
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hybridization studies have previously shown a co-expres-
sion, and receptor autoradiography indicates a co-local-
ization of A1 and A2A receptors in the hippocampus
(Cunha et al., 1994). In particular, both receptors are
localized in nerve terminals of the hippocampus
(Cunha et al., 1995). In addition, immunohistochemical
studies with selective A1 and A2A receptor antibodies
con¢rmed the localization of both receptors in hippo-
campal nerve terminals (Dia¤z-Hernandez et al. 2002).
Finally, it has previously been reported that activation
of A2A receptors decreases the binding a⁄nity of A1
receptor agonists in a manner dependent on intracellular
transducing systems and independent of the release of
mediators (Dixon et al., 1997; Lopes et al., 1999a).
The observations that CGS 21680 causes parallel
e¡ects on synaptic transmission and PPF and is also
able to facilitate glutamate release from isolated nerve
terminals are strong indications that presynaptic A2A
receptors are responsible for the e¡ects of CGS 21680
on synaptic transmission. However, it is important to
note that other electrophysiological studies in hippocam-
pal slices also identi¢ed responses apparently mediated
by postsynaptic A2A receptors (Li and Henry, 1998;
O’Kane and Stone, 1998), making it possible that A1/
A2A receptor interactions might also occur at the post-
synaptic level. However, A1 receptors control synaptic
transmission in the hippocampus mostly by activation
of presynaptic rather than postsynaptic A1 receptors
(Proctor and Dunwiddie, 1987). Therefore, it appears
that the presynaptic component is the main locus of of
A1/A2A receptor interaction involved in modulation of
hippocampal synaptic transmission. A2A receptors may
not always require A1 receptor-mediated inhibition to
show an e¡ect. There are several reports of A2A receptor
agonists modulating neurotransmitter release without
requiring A1 activation (Correia-de-Sa¤ et al., 1991;
Cunha et al., 1995; Cunha and Ribeiro, 2000a; Jin and
Fredholm, 1997; Gubitz et al., 1996; Okada et al., 2001).
Even at the glutamatergic synapses of the hippocampus,
it is possible to reveal an A2A receptor e¡ect dependent
on N-methyl-D-aspartate receptor activation (Nikbakht
and Stone, 2001). Therefore, A2A receptors can directly
facilitate transmission or ful¢ll a ¢ne-tuning role, acting
as modulators of other neuromodulatory systems
(Sebastia‹o and Ribeiro, 2000), depending on the condi-
tions and/or preparations, but it is not clearly under-
stood what controls the ability of A2A receptors to
modulate directly or indirectly neurotransmitter release.
One hypothesis is that this di¡erent role of A2A recep-
tors in di¡erent systems may be related to activation of
di¡erent transduction mechanisms. When A2A receptors
modulate neurotransmitter release independently of A1
receptor function, the rise in cAMP appears to be a
main requirement (Correia-de-Sa¤ and Ribeiro, 1994;
Gubitz et al., 1996; Okada et al., 2001). In contrast,
the e¡ects now reported appear to involve PKC recruit-
ment independently of cAMP. In accordance with our
previous ¢ndings in cortical slices from young rats
(Lopes et al., 1999b), we were now also unable to see
any variation in the levels of cAMP in hippocampal
nerve terminals upon activation of A2A receptors, while
activation of the GS/adenylate cyclase/cAMP coupled
with L-adrenergic receptor increased cAMP levels. Fur-
thermore, in contrast to the L-adrenergic receptor-medi-
ated e¡ect, the increase in the evoked release of
glutamate mediated by A2A receptors was prevented by
two di¡erent inhibitors of PKC but not inhibitors of
PKA, as previously described to occur for synaptic trans-
mission (Cunha and Ribeiro, 2000a). These data further
support the idea that A1/A2A receptor crosstalk in the
hippocampus is PKC- but not PKA-dependent (Lopes et
al., 1999a).
The present study also clearly excludes the involve-
ment of an A2A receptor e¡ect on GABAergic transmis-
sion for the control of CA1 hippocampal synaptic
transmission, in contrast with what has been shown to
occur in other neuronal circuits in the CNS (Phillis,
1998; Edwards and Robertson, 1999; but see Kobayashi
and Okada, 1999). Still, two possible roles for A2A recep-
tors on GABAergic systems need to be explored:
(1) modulation of GABAergic transmission in di¡erent
hippocampal areas, namely in the CA3 area where the
density and e¡ects of A2A receptors are more pro-
nounced (Cunha et al., 1994; Lopes et al., 1999b;
Gonc]alves et al., 1997) and (2) synchronization of hippo-
campal circuits, A2A receptors eventually being located in
GABAergic neurons that control other GABAergic neu-
rons (see Buckmaster and Soltesz, 1996). Both hypoth-
eses are compatible with the lack of involvement in
GABAergic control by A2A receptors in monosynaptic
glutamatergic circuits in the Scha¡er ¢ber/CA1 pyramid
synapses.
The physiological relevance of this proposed A2A
receptor-mediated attenuation of A1 receptors in the
control exerted by adenosine of hippocampal CA1 syn-
aptic transmission is probably dependent on the origin of
the adenosine released into the synaptic cleft. Adenosine
released as such through the bi-directional adenosine
transporters leads to a predominant A1 receptor activa-
tion, whereas the formation of adenosine from released
adenine nucleotides leads to a preferential activation of
facilitatory adenosine receptors (reviewed in Cunha,
2001). One might speculate that only in situations
where A1 receptors are not fully activated and when
there is a large release of adenine nucleotides, mainly
ATP, will this proposed A2A receptor-mediated attenua-
tion of A1 receptor-mediated inhibition be operative.
One such situation might be upon high frequency ¢ring
of Scha¡er ¢bers, since long-term potentiation (LTP)-
like stimulation induces a large release of adenine nucleo-
tides (Wieraszko et al., 1989). It is well known that
adenosine A1 receptors modulate LTP (de Mendonc]a
and Ribeiro, 1997) and the intensity of this e¡ect is sim-
ilar to that observed under basal stimulation conditions
in spite of the larger transient release of purines that
occurs (discussed in Cunha, 2001). The observation
that adenosine A2A receptor antagonists depress CA1
hippocampal LTP (e.g. Fujii et al., 2000) is in support
of a role for a tonic A2A receptor activation in LTP.
Likewise, both A2A receptor blockade and receptor dele-
tion in transgenic animals impair LTP in the mouse
nucleus accumbens without altering basal synaptic trans-
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mission (D’Alcantara et al., 2001). In contrast, in patho-
logical situations such as excitotoxicity, we anticipate
that this proposed A2A receptor-mediated attenuation
of A1 responses may have a discrete role.
CONCLUSION
The present results reveal the mechanism by which
A2A receptors cause a facilitation of synaptic transmis-
sion in the hippocampal CA1 area. The presently pro-
posed A2A receptor-mediated attenuation of A1 receptor
tonic inhibition may be a ¢ne-tuning mechanism to allow
frequency-dependent plasticity phenomena without com-
promising the A1 receptor-mediated neuroprotective role
of adenosine.
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